Detection of exosomal miRNAs in the plasma of melanoma patients

Journal of Clinical Medicine

Volumn 4, Issue 12, 2015, Pages 2012-2027

  Pfeffer, Susan R ^a   Grossmann, Kenneth F ^b   Cassidy, Pamela B ^c   Yang, Chuan He ^a   Fan, Meiyun ^a   Kopelovich, Levy ^d   Leachman, Sancy A ^c   Pfeffer, Lawrence M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Exosomes; Melanoma; Metastasis; miRNAs

Indexed keywords

ADDUCIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CD34 ANTIGEN; CRYOPYRIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH RECEPTOR 3; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INHIBITOR OF DIFFERENTIATION 2; LEUKOTRIENE B4 RECEPTOR; MICRORNA; MICRORNA 126; MICRORNA 149; MICRORNA 17; MICRORNA 19; MICRORNA 21; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN SYNTHASE; PROTEIN N MYRISTOYLTRANSFERASE; PROTEIN P16; PROTEIN P63; RETINOID RELATED ORPHAN RECEPTOR ALPHA; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT3; TRISTETRAPROLIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXOSOME; FEMALE; HUMAN; MALE; MELANOMA; MIDDLE AGED; MRNA EXPRESSION ASSAY; POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 85048753542     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4121957     Document Type: Article

References (54)

1. Vasudevan, S.; Tong, Y.; Steitz, J.A. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 2007, 318, 1931-1934. [CrossRef] [PubMed]
2. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297. [CrossRef]
3. Cho, W.C. Oncomirs: The discovery and progress of microRNAs in cancers. Mol. Cancer 2007, 6, 60. [CrossRef] [PubMed]
4. Rabinowits, G.; Gercel-Taylor, C.; Day, J.M.; Taylor, D.D.; Kloecker, G.H. Exosomal microRNA: A diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10, 42-46. [CrossRef] [PubMed]
5. Thery, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9, 581-593. [CrossRef] [PubMed]
6. Pegtel, D.M.; Cosmopoulos, K.; Thorley-Lawson, D.A.; van Eijndhoven, M.A.; Hopmans, E.S.; Lindenberg, J.L.; de Gruijl, T.D.; Wurdinger, T.; Middeldorp, J.M. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. USA 2010, 107, 6328-6333. [CrossRef] [PubMed]
7. Kottel, R.H.; Hoch, S.O.; Parsons, R.G.; Hoch, J.A. Serum ribonuclease activity in cancer patients. Br. J. Cancer 1978, 38, 280-286. [CrossRef] [PubMed]
8. Quackenbush, J.F.; Cassidy, P.B.; Pfeffer, L.M.; Boucher, K.M.; Hawkes, J.E.; Pfeffer, S.R.; Kopelovich, L.; Leachman, S.A. Isolation of circulating microRNAs from microvesicles found in human plasma. Methods Mol. Biol. 2014, 1102, 641-653. [PubMed]
9. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29. [CrossRef] [PubMed]
10. Aoude, L.G.; Wadt, K.A.; Pritchard, A.L.; Hayward, N.K. Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res. 2015, 28, 148-160. [CrossRef] [PubMed]
11. Eliason, M.J.; Larson, A.A.; Florell, S.R.; Zone, J.J.; Cannon-Albright, L.A.; Samlowski, W.E.; Leachman, S.A. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J. Investig. Dermatol. 2006, 126, 660-666. [CrossRef] [PubMed]
12. Goldstein, A.M.; Chan, M.; Harland, M.; Hayward, N.K.; Demenais, F.; Bishop, D.T.; Azizi, E.; Bergman, W.; Bianchi-Scarra, G.; Bruno, W.; et al. Features associated with germline CDKN2A mutations: A genomel study of melanoma-prone families from three continents. J. Med. Genet. 2007, 44, 99-106. [CrossRef] [PubMed]
13. Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arold, S.T.; Imielinski, M.; Theurillat, J.P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.; et al. A landscape of driver mutations in melanoma. Cell 2012, 150, 251-263. [CrossRef] [PubMed]
14. Stott, F.J.; Bates, S.; James, M.C.; McConnell, B.B.; Starborg, M.; Brookes, S.; Palmero, I.; Ryan, K.; Hara, E.; Vousden, K.H.; et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998, 17, 5001-5014. [CrossRef] [PubMed]
15. Bishop, D.T.; Demenais, F.; Goldstein, A.M.; Bergman, W.; Bishop, J.N.; de Paillerets, B.; Chompret, A.; Ghiorzo, P.; Gruis, N.; Hansson, J.; et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl. Cancer Inst. 2002, 94, 894-903. [CrossRef] [PubMed]
16. Fan, M.; Pfeffer, S.R.; Lynch, H.T.; Cassidy, P.; Leachman, S.; Pfeffer, L.M.; Kopelovich, L. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: Relevance to early intervention. Oncotarget 2013, 4, 128-141. [CrossRef] [PubMed]
17. Caramuta, S.; Egyhazi, S.; Rodolfo, M.; Witten, D.; Hansson, J.; Larsson, C.; Lui, W.O. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Investig. Dermatol. 2010, 130, 2062-2070. [CrossRef] [PubMed]
18. Glud, M.; Klausen, M.; Gniadecki, R.; Rossing, M.; Hastrup, N.; Nielsen, F.C.; Drzewiecki, K.T. MicroRNA expression in melanocytic nevi: The usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J. Investig. Dermatol. 2009, 129, 1219-1224. [CrossRef] [PubMed]
19. Segura, M.F.; Belitskaya-Levy, I.; Rose, A.E.; Zakrzewski, J.; Gaziel, A.; Hanniford, D.; Darvishian, F.; Berman, R.S.; Shapiro, R.L.; Pavlick, A.C.; et al. Melanoma microRNA signature predicts post-recurrence survival. Clin. Cancer Res. 2010, 16, 1577-1586. [CrossRef] [PubMed]
20. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci USA 2008, 105, 10513-10518. [CrossRef] [PubMed]
21. Talantov, D.; Mazumder, A.; Yu, J.X.; Briggs, T.; Jiang, Y.; Backus, J.; Atkins, D.; Wang, Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 2005, 11, 7234-7242. [CrossRef] [PubMed]
22. Smith, A.P.; Hoek, K.; Becker, D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol. Ther. 2005, 4, 1018-1029. [CrossRef] [PubMed]
23. Jaeger, J.; Koczan, D.; Thiesen, H.J.; Ibrahim, S.M.; Gross, G.; Spang, R.; Kunz, M. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res. 2007, 13, 806-815. [CrossRef] [PubMed]
24. Molecular Signatures Database v5. 0. Available online: http: //software. broadinstitute. org/gsea/index. jsp (accessed on 30 June 2015).
25. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545-15550. [CrossRef] [PubMed]
26. Lim, L.P.; Lau, N.C.; Garrett-Engele, P.; Grimson, A.; Schelter, J.M.; Castle, J.; Bartel, D.P.; Linsley, P.S.; Johnson, J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433, 769-773. [CrossRef] [PubMed]
27. Reid, G.; Kirschner, M.B.; van Zandwijk, N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit. Rev. Oncol. Hematol. 2011, 80, 193-208. [CrossRef] [PubMed]
28. Friedman, E.B.; Shang, S.; de Miera, E.; Fog, J.U.; Teilum, M.W.; Ma, M.W.; Berman, R.S.; Shapiro, R.L.; Pavlick, A.C.; Hernando, E.; et al. Serum microRNAs as biomarkers for recurrence in melanoma. J. Trans. Med. 2012, 10, 155. [CrossRef] [PubMed]
29. Kanemaru, H.; Fukushima, S.; Yamashita, J.; Honda, N.; Oyama, R.; Kakimoto, A.; Masuguchi, S.; Ishihara, T.; Inoue, Y.; Jinnin, M.; et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 2011, 61, 187-193. [CrossRef] [PubMed]
30. Greenberg, E.; Hershkovitz, L.; Itzhaki, O.; Hajdu, S.; Nemlich, Y.; Ortenberg, R.; Gefen, N.; Edry, L.; Modai, S.; Keisari, Y.; et al. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS ONE 2011, 6, e18936. [CrossRef] [PubMed]
31. Wong, P.; Iwasaki, M.; Somervaille, T.C.; Ficara, F.; Carico, C.; Arnold, C.; Chen, C.Z.; Cleary, M.L. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 2010, 70, 3833-3842. [CrossRef] [PubMed]
32. Rao, E.; Jiang, C.; Ji, M.; Huang, X.; Iqbal, J.; Lenz, G.; Wright, G.; Staudt, L.M.; Zhao, Y.; McKeithan, T.W.; et al. The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via pi3k/akt pathway activation. Leukemia 2012, 26, 1064-1072. [CrossRef] [PubMed]
33. Hayashita, Y.; Osada, H.; Tatematsu, Y.; Yamada, H.; Yanagisawa, K.; Tomida, S.; Yatabe, Y.; Kawahara, K.; Sekido, Y.; Takahashi, T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65, 9628-9632. [CrossRef] [PubMed]
34. Ebi, H.; Sato, T.; Sugito, N.; Hosono, Y.; Yatabe, Y.; Matsuyama, Y.; Yamaguchi, T.; Osada, H.; Suzuki, M.; Takahashi, T. Counterbalance between rb inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009, 28, 3371-3379. [CrossRef] [PubMed]
35. Levy, C.; Khaled, M.; Iliopoulos, D.; Janas, M.M.; Schubert, S.; Pinner, S.; Chen, P.H.; Li, S.; Fletcher, A.L.; Yokoyama, S.; et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol. Cell 2010, 40, 841-849. [CrossRef] [PubMed]
36. Wu, Q.; Yang, Z.; An, Y.; Hu, H.; Yin, J.; Zhang, P.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis. 2014, 5, e1144. [CrossRef] [PubMed]
37. Lepore, I.; Dell'Aversana, C.; Pilyugin, M.; Conte, M.; Nebbioso, A.; de Bellis, F.; Tambaro, F.P.; Izzo, T.; Garcia-Manero, G.; Ferrara, F.; et al. HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. PLoS ONE 2013, 8, e83018. [CrossRef] [PubMed]
38. Si, M.L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y.Y. MiR-21-mediated tumor growth. Oncogene 2007, 26, 2799-2803. [CrossRef] [PubMed]
39. Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257-2261. [CrossRef] [PubMed]
40. Folini, M.; Gandellini, P.; Longoni, N.; Profumo, V.; Callari, M.; Pennati, M.; Colecchia, M.; Supino, R.; Veneroni, S.; Salvioni, R.; et al. miR-21: An oncomir on strike in prostate cancer. Mol. Cancer 2010, 9, 12. [CrossRef] [PubMed]
41. Loffler, D.; Brocke-Heidrich, K.; Pfeifer, G.; Stocsits, C.; Hackermuller, J.; Kretzschmar, A.K.; Burger, R.; Gramatzki, M.; Blumert, C.; Bauer, K.; et al. Interleukin-6 dependent survival of multiple myeloma cells involves the stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110, 1330-1333. [CrossRef] [PubMed]
42. Chan, J.A.; Krichevsky, A.M.; Kosik, K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65, 6029-6033. [CrossRef] [PubMed]
43. Zhu, S.; Wu, H.; Wu, F.; Nie, D.; Sheng, S.; Mo, Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18, 350-359. [CrossRef] [PubMed]
44. Wang, P.; Zou, F.; Zhang, X.; Li, H.; Dulak, A.; Tomko, R.J., Jr.; Lazo, J.S.; Wang, Z.; Zhang, L.; Yu, J. MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009, 69, 8157-8165. [CrossRef] [PubMed]
45. Sheedy, F.J. Turning 21: Induction of miR-21 as a key switch in the inflammatory response. Front. Immunol. 2015, 6, 19. [CrossRef] [PubMed]
46. Yang, C.H.; Yue, J.; Fan, M.; Pfeffer, L.M. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010, 70, 8108-8116. [CrossRef] [PubMed]
47. Yang, C.H.; Yue, J.; Pfeffer, S.R.; Handorf, C.R.; Pfeffer, L.M. MicroRNA miR-21 regulates the metastatic behavior of b16 melanoma cells. J. Biol. Chem. 2011, 286, 39172-39178. [CrossRef] [PubMed]
48. Jiang, L.; Lv, X.; Li, J.; Li, J.; Li, X.; Li, W.; Li, Y. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochem. 2012, 114, 582-588. [CrossRef] [PubMed]
49. Felli, N.; Felicetti, F.; Lustri, A.M.; Errico, M.C.; Bottero, L.; Cannistraci, A.; de Feo, A.; Petrini, M.; Pedini, F.; Biffoni, M.; et al. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS ONE 2013, 8, e56824. [CrossRef] [PubMed]
50. Jin, L.; Hu, W.L.; Jiang, C.C.; Wang, J.X.; Han, C.C.; Chu, P.; Zhang, L.J.; Thorne, R.F.; Wilmott, J.; Scolyer, R.A.; et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc. Natl. Acad. Sci. USA 2011, 108, 15840-15845. [CrossRef] [PubMed]
51. Sauroja, I.; Smeds, J.; Vlaykova, T.; Kumar, R.; Talve, L.; Hahka-Kemppinen, M.; Punnonen, K.; Jansen, C.T.; Hemminki, K.; Pyrhonen, S. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000, 28, 404-414. [CrossRef]
52. Perrot, C.Y.; Javelaud, D.; Mauviel, A. Insights into the transforming growth factor-beta signaling pathway in cutaneous melanoma. Ann. Dermatol. 2013, 25, 135-144. [CrossRef] [PubMed]
53. Lynch, H.T.; Fusaro, R.M.; Lynch, J.F.; Brand, R. Pancreatic cancer and the fammm syndrome. Fam. Cancer 2008, 7, 103-112. [CrossRef] [PubMed]
54. TCGA Data Portal. Available online: https: //tcga-data. nci. nih. gov/tcga/tcgaHome2. jsp (accessed on 23 July 2015).